EYNZYMES IN HEART

心脏中的酶

• 批准号: 2234451
• 负责人: Carleton Hsia
• 金额: $ 10万
• 依托单位: SYNZYME TECHNOLOGY, INC.
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-05-01 至 1998-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2234451
• 关键词: EYNZYMES; HEART

A preliminary study has demonstrated that the new drug polynitroxyl albumin (PNA) gives unprecedented protection against brain damage in an animal model of focal cerebral ischemia/reperfusion (stroke). PNA treatment at the onset of reperfusion provided essentially complete protection against brain damage. Because there are general similarities in the pathophysiology of reperfusion injury in different organs, and because myocardial ischemia/reperfusion injury is a leading case of morbidity and mortality, the Company proposes to test whether PNA offers similar protection in the heart. PROPOSED COMMERCIAL APPLICATION: Myocardial ischemia/reperfusion injury is a leading cause of morbidity and mortality. If SynZyme were proven to have efficacy in protecting the heart against this injury, potential clinical applications would include use an adjunct to thrombolytic therapy in acute myocardial infarction, post-cardioplegia reperfusion in cardiac surgery, and coronary angioplasty.

一项初步研究表明，新药多硝基羟基白蛋白 （PNA）为动物的脑损伤提供了前所未有的保护 局灶性脑缺血/再灌注的模型（中风）。 PNA处理 再灌注的发作基本上提供了针对的完全保护 脑损伤。 因为在 在不同器官中再灌注损伤的病理生理学，因为 心肌缺血/再灌注损伤是发病率和 死亡率，公司建议测试PNA是否提供类似的 心脏保护。 拟议的商业应用：心肌缺血/再灌注损伤是 发病率和死亡率的主要原因。 如果被证明具有 保护心脏免受这种伤害的疗效，潜在的临床 应用包括在急性中使用辅助疗法 心肌梗死，心脏外科手术后的再灌注后， 和冠状动脉成形术。